Construction of RNA Research and Pilot Manufacturing Facility on track with main works contract awarded
Australia’s first-of-its-kind RNA Research and Pilot Manufacturing Facility is a step closer to reality, with the appointment of the main works contractor Hindmarsh Construction.
The cutting-edge facility will reduce Australias reliance on international supply and provide patients with faster access to new therapies for hard-to-treat diseases such as cancer and rare genetic disorders.
Located in the Connect Macquarie Park Innovation District at Macquarie University, the new facility will be operated by Myeloid Therapeutics, a global therapeutics company.
The NSW Government has committed $96 million for the facility, with a further $119 million announced over 10 years for RNA research and development projects.
The project is being delivered by Health Infrastructure on behalf of the Office of the NSW Chief Scientist Engineer.
Construction is expected to commence in the coming months and the facility is expected to be operational in 2026.